Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report
Open accessAbstract
Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report Jacqui WiseThe rheumatoid arthritis drug tocilizumab seems to improve outcomes in patients with covid-19 who are the most severely ill, show early results released from the Remap-Cap international platform trial.The researchers reported that critically ill patients receiving tocilizumab were more likely to improve than patients who received no immune modulator (odds ratio 1.87)."These are very exciting and encouraging results," said the chief investigator, Anthony Gordon, consultant in intensive care medicine at Imperial College Healthcare NHS Trust, at a Science Media Centre briefing on 19 November.He said that this was a bigger result than the 1.43 odds ratio seen with the steroid dexamethasone reported earlier by the trial.Griffin S. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362 · see citing works
Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds
Griffin, S. (2020) · BMJ · doi:10.1136/bmj.m2650 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The struggle of a good friend getting old: cellular senescence in viral responses and therapy
Kohli, J., Veenstra, I., & Demaria, M. (2021) · The EMBO Reports · doi:10.15252/embr.202052243 · Cited by 52 · see citing works
- Authors
- Wise, J.
- Corresponding author
- Wise, Jacqui
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2020-11-19
- Volume
- 371
- Pages
- m4530
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3098423618
- Cited by
- 19
- References
- 2
- Citations by year
- 2023: 3 · 2022: 2 · 2021: 13 · 2020: 1
- Type
- other
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, tocilizumab, critically ill patients, immunomodulators, dexamethasone, lopinavir/ritonavir, treatment outcomes, rheumatoid arthritis drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
